Last month, Fate Therapeutics (FATE) reported additional data for their two off-the-shelf NK cell programs. This was an important event because it would read-through to NK players like Affimed (AFMD), NKarta (NKTX), Artiva (ARTV) and others. Overall, the data was okay. Not a homerun, but also far from a flop. The data was enticing enough to warrant seei…
© 2024 Bohdan (Bo) Khomtchouk, Ph.D.
Substack is the home for great writing